Regional Access to Services among Individuals with Hepatitis C in Ontario

An estimated 71 million people worldwide live with chronic hepatitis C virus (HCV) infection which, if left untreated, can increase morbidity and mortality. Direct-acting antivirals (DAAs) are curative treatments for HCV. However, initiation of these treatments depends on access to health care and physicians that can diagnose and initiate treatment.

The COVID-19 pandemic resulted in restrictions to healthcare services in March 2020. Delays in diagnosis and interruptions in care lead to patients being lost to follow-up, producing negative health outcomes and ongoing transmission.

The following maps examine trends in HCV DAA medication prescribing and the average distance to a prescriber by public health unit in Ontario in 2019.

Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.